Podcast Pearls: Advances Across B Cell Lymphomas

Source: A Class in Session: Understanding Current and Future Therapeutic Advances Across B-Cell Lymphomas
Download PDF
In these notes from a podcast, read expert insights from Julie M. Vose, MD, MBA; Brad S. Kahl, MD; and John P. Leonard, MD, on treatment options for patients with B-cell lymphomas from a recent symposium held during the annual Hematology meeting in 2021.
Julie M. Vose, MD, MBA
Program Director
Brad S. Kahl, MD
John P. Leonard, MD
Format: Adobe Acrobat (.pdf)
File Size: 271 KB
Released: February 25, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Atara Biotherapeutics, Inc.
Bayer HealthCare Pharmaceuticals Inc.
BeiGene, Ltd.
Epizyme
Genentech, a member of the Roche Group
Genmab US, Inc.
Incyte Corporation
Karyopharm Therapeutics
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.

Information on this Educational Activity

Program Director

Julie M. Vose, MD, MBA

Chief, Division of Oncology and Hematology
Neumann M. and Mildred E. Harris Professor
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Julie M. Vose, MD, MBA, has disclosed that she has received funds for research support from Acerta/AstraZeneca, Celgene/Bristol-Myers Squibb, Epizyme, Incyte, Kite, Loxo, Novartis, and Seattle Genetics and consulting fees from AbbVie, Acerta/AstraZeneca, Conjupro, Janssen/Pharmacyclics, Johnson & Johnson, Kite, Morphosis, Oncternal, Roche/Genentech, and Vaniam Group.

Faculty

Brad S. Kahl, MD

Professor of Medicine
Department of Medical Oncology
Washington University School of Medicine
St Louis, Missouri

Brad S. Kahl, MD, has disclosed that he has received funds for research support from AbbVie, ADCT, AstraZeneca, BeiGene, and Genentech and consulting fees from AbbVie, Adaptive, ADCT, AstraZeneca, Bayer, BeiGene, Bristol-Myers Squibb, Celgene, Genentech, Incyte, Janssen, Karyopharm, Kite, MEI, Pharmacyclics, Roche, and Teva.
John P. Leonard, MD

Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Professor of Medicine
Weill Cornell Medicine
New York Presbyterian Hospital
New York, New York

John P. Leonard, MD, has disclosed that he has received funds for research support from Genentech and consulting fees from AbbVie, AstraZeneca, Bayer, Bristol-Myers Squibb/Celgene, Epizyme, Genentech/Roche, Genmab, Gilead Sciences/Kite, Incyte, Janssen, Karyopharm, MEI Pharma, Miltenyi, Regeneron, and Sutro.

Program Medium

This program has been made available online.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings